Oral compositions for the treatment of non-diabetic obese mammals, including humans

Oral compositions containing an effective amount of a tungsten compound (VI), preferably a tungstate salt, more preferably sodium tungstate (Na2WO4), are useful in controlling obesity/overweightness in non-diabetic mammals, including humans. The anti-obesity effect of sodium tungstate dihydrate in r...

Full description

Saved in:
Bibliographic Details
Main Authors GUINOVART CIRERA JOAN-JOSEP, FERNANDEZ ALVAREZ JOSEFA, GOMIS DE BARBARA RAMON, CLARET CARLES MARC
Format Patent
LanguageEnglish
Published 17.10.2006
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Oral compositions containing an effective amount of a tungsten compound (VI), preferably a tungstate salt, more preferably sodium tungstate (Na2WO4), are useful in controlling obesity/overweightness in non-diabetic mammals, including humans. The anti-obesity effect of sodium tungstate dihydrate in rats has been determined in a cafeteria-diet-induced obesity model. Said obese rats are good models of obese, non-diabetic mammals, including humans. The prophylactic, therapeutic and/or cosmetic treatment resulting from this invention is surprising. It provides advantages such as effectiveness, lack of toxicity and relatively low price in comparison with other treatments in prior art. Hence, the oral compositions according to the invention are useful for the treatment of obesity/overweightness in non-diabetic mammals, including humans.
Bibliography:Application Number: US20030477807